Skip to content

Evaluating the Effectiveness of Treatment for Metacognition in Moderate and Severe Traumatic Brain Injury

Evaluating the Effectiveness of Treatment for Metacognition in Moderate and Severe Traumatic Brain Injury

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03169647
Enrollment
18
Registered
2017-05-30
Start date
2017-08-17
Completion date
2019-06-30
Last updated
2019-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injuries, Traumatic

Brief summary

Metacognition, in-the-moment awareness of performance while engaging in cognitive tasks, is negatively affected by traumatic brain injury (TBI). Metacognitive deficits can greatly reduce quality of life for individuals with TBI as functioning in this domain has been closely linked with successful independent living and community re-integration. Problematically, there are currently no empirically validated treatment options that address metacognitive deficits after TBI. Recent research in healthy samples demonstrates that specific listening interventions may alter neural activation in brain works associated with metacognition and can improve metacognitive functioning; however, it remains unknown if these effects generalize to individuals with TBI. Thus, the objective of the proposed study is to use a double-blind, placebo controlled randomized clinical trial to determine the efficacy of applying a specific listening intervention to improve metacognition after TBI and to employ functional magnetic resonance imaging (fMRI) to document the neural mechanisms by which the intervention operates.

Interventions

BEHAVIORALListening-based intervention

Participants will listen to pre-specified material on a CD

Sponsors

Kessler Foundation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 59 Years
Healthy volunteers
No

Inclusion criteria

* diagnosis of moderate or severe brain injury * between the ages of 18 and 59. * able to read and speak English fluently. * TBI at least 1 year ago.

Exclusion criteria

* pregnant. * left-handed. * color-blind. * diagnosed with significant psychiatric illness (e.g., bipolar, schizophrenia). * receiving or have received inpatient and/or rehabilitative treatment for substance use. * diagnosis of a neurological condition other than TBI (e.g., epilepsy, multiple sclerosis, stroke). * any metal in my body that has not been declared MRI-safe by my physician. * impaired independent use of either hand. * any of the following in/on my body that may interfere with MRI: pacemaker, implanted electrical devices, brain stimulators, particular types of dental implants, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves, and internal hearing aids), permanent eyeliner, implanted delivery pumps, or shrapnel fragments. * history of engaging in welding and/or metal working activities. * formal training or am a current practitioner of yoga, meditation, and/or mindfulness. * currently involved in any other type of thinking skills and/or emotional treatment, such as psychotherapy.

Design outcomes

Primary

MeasureTime frameDescription
Goodman and Kruskal gamma coefficient on MRI-based metacognitive task7 weeksWhile participants are in the scanner, they will perform a metamemory paradigm that involves the completion of 2 components per trial: 1) a memory task (a non-verbal recognition task), and 2) a metacognitive task that immediately follows completion of every recognition item. Accuracy of metacognitive functioning can be quantified using the Goodman and Kruskal gamma coefficient,16 a value between -1 and 1, indicating the discrepancy between the participant's judgment and objective performance that is commonly used in the metacognitive literature.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026